WD-40 Company (WDFC)
NASDAQ: WDFC · Real-Time Price · USD
215.20
+0.80 (0.37%)
At close: Aug 1, 2025, 4:00 PM
218.00
+2.80 (1.30%)
After-hours: Aug 1, 2025, 7:21 PM EDT
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 3 analysts that cover Intra-Cellular Therapies stock have a consensus rating of "Strong Buy" and an average price target of $300.67, which forecasts a 39.72% increase in the stock price over the next year. The lowest target is $280 and the highest is $322.
Price Target: $300.67 (+39.72%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Intra-Cellular Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| DA Davidson | DA Davidson | Strong Buy Maintains $322 → $300 | Strong Buy | Maintains | $322 → $300 | +39.41% | Jul 11, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $322 | Strong Buy | Maintains | $322 | +49.63% | Jan 27, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $322 | Strong Buy | Maintains | $322 | +49.63% | Jan 21, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $322 | Strong Buy | Maintains | $322 | +49.63% | Nov 18, 2024 |
| Jefferies | Jefferies | Hold Maintains $250 → $280 | Hold | Maintains | $250 → $280 | +30.11% | Oct 18, 2024 |
Financial Forecast
Revenue This Year
626.50M
from 590.56M
Increased by 6.09%
Revenue Next Year
662.61M
from 626.50M
Increased by 5.76%
EPS This Year
5.65
from 5.11
Increased by 10.66%
EPS Next Year
6.08
from 5.65
Increased by 7.59%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 648.9M | 682.8M | 728.7M |
| Avg | 626.5M | 662.6M | 707.9M |
| Low | 598.2M | 636.0M | 680.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 9.9% | 9.0% | 10.0% |
| Avg | 6.1% | 5.8% | 6.8% |
| Low | 1.3% | 1.5% | 2.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 5.82 | 6.30 | 6.93 |
| Avg | 5.65 | 6.08 | 6.73 |
| Low | 5.43 | 5.81 | 6.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.9% | 11.4% | 13.9% |
| Avg | 10.7% | 7.6% | 10.6% |
| Low | 6.3% | 2.8% | 6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.